2^nd Targeting Therapy of Alzheimer’s and Related Neurodegenerative Diseases Virtual Conference

Neurodegenerative diseases such as Alzheimer’s, Parkinson’s, FTS and ALS affect over 5 million people in the US and over 35 million people worldwide. Alzheimer’s disease (AD) is the most common age-dependent neurodegenerative disease and currently, only four drugs are approved for alleviating symptoms in AD patients, with no new therapies approved by FDA since 2003. Other related neurodegenerative diseases such as Parkinson’s disease (PD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS) are also age-dependent and lack effective therapies. Hence, finding cures for AD and other related neurodegenerative diseases is urgent and various approaches should be actively pursued. This planned conference intends to bring leading scientists and clinicians from all over the world to present their unpublished observations or findings to attendees and to share their vision or prospects on translational research. We expect that some presenters, either by talks or posters, will discuss our current state of knowledge in disease mechanisms, novel targets, new genetic association or pathways, approaches for identifying new therapeutic targets, and biomarkers for diagnosis or treatment readouts. We will also invite speakers who are conducting later stages of drug discoveries to share clinical trial results. The talks and poster presentations will include the most updated therapeutic strategies, newly discovered therapeutic targets, and recent clinical developments at various stages in the area of Alzheimer’s and related neurodegenerative diseases. 

Key topics of discussion will include:

• BACE1 inhibitors and/or γ-secretase modulators for reducing amyloid deposition
• Active and passive vaccination for enhancing clearance of amyloid plaques
• Vaccines for reducing tau pathology
• Antisense approaches for AD, PD and ALS therapy
• Neural stem cell approaches for neurodegeneration
• Inflammatory modulators for neurodegeneration.
• Genetic linkage study and big data approaches
• Novel therapeutic targets

The significance of having this conference is to provide a unique forum for the research community focusing on translational studies geared towards therapies in AD and related neurodegenerative diseases to come together to discuss the latest advances and the future challenges in the field.  

Confirmed Keynote Speakers

Ed Boyden (MIT)
NOVEL TOOLS FOR ANALYZING AND REPAIRING THE BRAIN IN ALZHEIMER'S DISEASE
Christine Van Broeckhoven (University of Antwerp)
RELEVANCE OF NOVEL GENES IDENTIFIED IN FAMILIES WITH ALZHEIMER’S OR RELATED NEURODEGENERATIVE DISEASES FOR TARGETED THERAPY
Anne Schaefer (Icahn School of Medicine at Mount Sinai)

Confirmed Invited Speakers

Guojun Bu (Mayo Clinic)
Li Gan (Weill Cornell Medical College)
MALADAPTIVE MICROGLIA DRIVE NEUROTOXICITY IN TAUOPATHY
Yadong Huang (Gladstone Institutes)
NEURONAL ApoE DRIVE SELECTIVE NEURODEGENERATION IN ALZHEIMER'S DISEASE
Nancy Ip (The Hong Kong University of Science and Technology)
UNDERSTANDING INNATE IMMUNITY IN ALZHEIMER'S DISEASE – INSIGHTS FOR DEVELOPMENT OF THERAPEUTICS
Manolis Kellis (MIT)
SINGLE-CELL DISSECTION OF NEURODEGENERATIVE DISEASE CIRCUITRY
Jonathan Kipnis (Washington University School of Medicine in St. Louis)
MENINGEAL LYMPHATICS AS A THERAPEUTIC TARGET IN AD
Ken Kosik (UC Santa Barbara)
Yueming Li (Memorial Sloan Kettering Cancer Center)
INNATE IMMUNITY AND G-SECRETASE
Shane Liddelow (NYU Langone Health)
THE ROLE OF REACTIVE ASTROCYTE SUB-STATES IN ALZHEIMER’S DISEASE
Andreas Pfenning (Carnegie Mellon University)
Domenico Pratico (Temple University)
SORTING OUT TRAFFIC JAM IN ALZHEIMER’S DISEASE AND RELATED TAUOPATHIES
Annabelle Singer (Emory University)
NEW APPROACHES TO ALZHEIMER’S: FROM NEURAL DEFICITS TO NEURAL STIMULATION
Sam Sisodia (University of Chicago)
ROLE OF THE GUT MICROBIOME IN MODULATION OF Aβ AMYLOIDOSIS AND MICROGLIAL FUNCTION
Bob Vasser (Northwestern University)

Grants

We have complimentary registrations available for postdocs and students. Please submit an abstract for oral or poster consideration via email to Amy, along with a short message outlining why you would benefit from attending this conference. Applications must be submitted by 23^rd August 2021 for consideration.

Abstract Submission

Please send oral and poster abstract submissions via email to the Conference Manager, Amy. The oral and poster deadlines are noted above. We advise early submission to avoid disappointment due to limited slots.

Target Audience

To bring junior investigators from academic labs and industries to present and closely interact with leading scientists in the field. We anticipate international representation from the US, Europe, Canada, Japan, Korea, China, and others. 

Educational Need

Junior investigators such as graduate students or postdoctoral fellows as well as clinician scientists are expected to gain knowledge on the most current therapeutic strategies in AD and the related field.  

We offer two price options for our virtual conferences. Please see below for details. If you register for a conference via our website, credit card payment is required. If you would prefer to pay via bank transfer, please contact us for an alternative registration method.

Standard Registration Fee: £217

This price grants access to the virtual conference for one user. Please note, your account is designed for single use. If another user tries to log into your account to access the virtual conference at the same time, the original user will be logged out immediately.

Lab Package Registration Fee: £500

This price grants access to the virtual conference for three users from the same lab. Please contact us if you are interested in this package for further details. 

Grants

We have complimentary registrations available for postdocs and students. Please submit an abstract for oral or poster consideration via email to Amy, along with a short message outlining why you would benefit from attending this conference. Applications must be submitted by 23^rd August 2021 for consideration.

Refund Policy

Please note refunds can only be issued within 14 days of booking. Outside of this, all registration fees are non-refundable. Please see our Terms and Conditions for further details.